NRVANDANA stock news
This page provides real-time market news, earnings updates, and company announcements related to N R Vandana Tex Industries Limited (NRVANDANA).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-05-13 00:34 IST
CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
Finviz2026-04-06 10:33:42
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Finviz2026-04-06 13:03:55
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Finviz2026-04-07 12:03:48
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix Utilization
Finviz2026-04-07 12:33:48
GRAIL Announces Integration of the Galleri Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Finviz2026-04-07 20:03:38
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
Finviz2026-04-08 10:03:59
SunTx Capital Partners' Portfolio Company, Suncrete, and Haymaker Acquisition Corp. 4, Successfully Complete Business Combination
Finviz2026-04-08 20:18:40
Robin Energy Ltd. Reports Results for the Three Months Ended December 31, 2025 and for the Year Ended December 31, 2025.
Finviz2026-04-10 13:06:56
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Finviz2026-04-10 21:06:48
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Finviz2026-04-13 10:48:09
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Finviz2026-04-13 11:03:44
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Garmin unveils D2 Mach 2 Pro, its first aviator smartwatch with inReach technology
Finviz2026-04-14 11:00:53
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Finviz2026-04-14 11:00:53
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Finviz2026-04-14 12:06:47
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA (valbenazine) Capsules Compared to AUSTEDO XR
Finviz2026-04-14 12:33:59
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Finviz2026-04-14 20:06:56
The Cook era ends, Apple is about to enter the "Ternus era": a power transition after 14 years of tenfold market value growth
金融界2026-04-22 00:02:10
Aethir infrastructure secures a $260 million enterprise-level contract from Axe Compute, providing further substantial validation for the ATH ecosystem flywheel.
BlockBeats2026-04-23 09:53:05
Game on for GME? (Potential Breakout)
TradingView2026-04-23 21:15:19
INTC heads up into $97: Triple Golden fibs may form a/the TOP
TradingView2026-04-30 04:15:16
CAT heads up into $900: Dual Fibs defending Round Number
TradingView2026-05-01 08:48:16
Soaring over 20%! Second in the world! FDA approves Alzheimer’s agitation indication! Axsome drug Auvelity becomes the first non-antipsychotic medication in the U.S. for Alzheimer’s disease agitation!
美股ipo2026-05-05 11:48:59
Joby Aviation: Visionary Mobility or Venture Capital in Public M
TradingView2026-05-07 14:45:21
GRAIL Announces Integration of the Galleri Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Finviz2026-04-07 20:03:38
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
Finviz2026-04-08 10:03:59
SunTx Capital Partners' Portfolio Company, Suncrete, and Haymaker Acquisition Corp. 4, Successfully Complete Business Combination
Finviz2026-04-08 20:18:40
Robin Energy Ltd. Reports Results for the Three Months Ended December 31, 2025 and for the Year Ended December 31, 2025.
Finviz2026-04-10 13:06:56
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Finviz2026-04-10 21:06:48
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Finviz2026-04-13 10:48:09
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Finviz2026-04-13 11:03:44
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Garmin unveils D2 Mach 2 Pro, its first aviator smartwatch with inReach technology
Finviz2026-04-14 11:00:53
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Finviz2026-04-14 11:00:53
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Finviz2026-04-14 12:06:47
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA (valbenazine) Capsules Compared to AUSTEDO XR
Finviz2026-04-14 12:33:59
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Finviz2026-04-14 20:06:56
The Cook era ends, Apple is about to enter the "Ternus era": a power transition after 14 years of tenfold market value growth
金融界2026-04-22 00:02:10
Aethir infrastructure secures a $260 million enterprise-level contract from Axe Compute, providing further substantial validation for the ATH ecosystem flywheel.
BlockBeats2026-04-23 09:53:05
Game on for GME? (Potential Breakout)
TradingView2026-04-23 21:15:19
INTC heads up into $97: Triple Golden fibs may form a/the TOP
TradingView2026-04-30 04:15:16
CAT heads up into $900: Dual Fibs defending Round Number
TradingView2026-05-01 08:48:16
Soaring over 20%! Second in the world! FDA approves Alzheimer’s agitation indication! Axsome drug Auvelity becomes the first non-antipsychotic medication in the U.S. for Alzheimer’s disease agitation!
美股ipo2026-05-05 11:48:59
Joby Aviation: Visionary Mobility or Venture Capital in Public M
TradingView2026-05-07 14:45:21
NRVANDANA stock price change
On the last trading day, NRVANDANA stock closed at 64.00 INR, with a price change of -1.77% for the day.
Trade stock perpsNRVANDANA stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more